Navigation Links
Rigel Announces Initiation of Clinical Trials in Two Immunology Programs
Date:1/5/2012

SOUTH SAN FRANCISCO, Calif., Jan. 5, 2012 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL: Nasdaq) today announced that two of its lead product candidates entered clinical trials during the fourth quarter of 2011. The company is evaluating R548, an oral JAK3 inhibitor, as a potential therapeutic for transplant rejection and other systemic immune disorders. The second candidate, R333, is a topical JAK/SYK inhibitor aimed at treating various phases of discoid lupus (lupus of the skin). Rigel's product pipeline will be the focus of the company's presentation at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 9th at 1:30 pm Pacific Time (webcast details below).

"Rigel continues to be one of the most productive companies in the biopharmaceutical sector, as evidenced by the commencement of First in Human (FIH) studies in two programs this past quarter," said James M. Gower, chairman and chief executive officer of Rigel. "The goal of our highly-talented 155 person R&D-focused organization is to add at least one new product candidate into the clinic each year for the foreseeable future and move those into proof-of-concept trials. We plan to have Phase 2 trial results in three internal programs in 2013," he added

R548, JAK3 Inhibitor

Transplant rejection is an area of tremendous medical need. While 90% of patients survive the first year after receiving the transplanted organ, chronic organ rejection rates rise to 50% within the five to ten years following surgery. Currently available therapeutics are not sufficient to help these patients achieve lasting recovery. Furthermore, transplants of certain organs are rarely done because of the inadequacies of these therapies. Rigel's R548 is a JAK3 inhibitor that is expected to moderate the immune system's response to the allograft and improve patient outcomes. R548 may also have application in tre
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rigel to Present at Oppenheimer Annual Healthcare Conference
2. Rigel Announces Third Quarter 2011 Financial Results
3. Rigel to Present at Two Upcoming Investor Conferences
4. Rigel to Present at Wells Fargo Securities Healthcare Conference
5. Rigel to Present at Jefferies Global Healthcare Conference
6. Rigel Announces Pricing of Public Offering of Common Stock
7. Rigel Announces Proposed Public Offering of Common Stock
8. Rigel to Present at Bank of America Merrill Lynch Health Care Conference
9. Rigel Announces First Quarter Financial Results
10. Rigel Announces Fourth Quarter and Year End 2010 Financial Results
11. Rigel to Present at Three Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015  RegeneRx Biopharmaceuticals, Inc. ... drug development company focused on tissue protection, repair ... , President and Chief Executive Officer, will present ... Global Investment Conference, sponsored by H.C. Wainwright ... September 8-10, 2015 at the St. Regis Hotel ...
(Date:9/2/2015)... Calif. , Sept. 2, 2015 BioPharmX Corporation ... announced that Jim Pekarsky , chief executive officer and ... 17th Annual Global Investment Conference taking place, September 8-10, 2015 ... . Mr. Pekarsky is scheduled to present on ... Suite A (2 nd floor). A live ...
(Date:9/2/2015)... and MENLO PARK, Calif. , ... (OTCQX: DMPI) ("DelMar" and the "Company"), a ... of new cancer therapies, today announced that it ... of the Mechanisms and Cytotoxic Activity of Dianhydrogalactitol ... Wild-type and Mutant p53," at the American ...
Breaking Medicine Technology:RegeneRx to Present at Rodman & Renshaw Global Investment Conference 2RegeneRx to Present at Rodman & Renshaw Global Investment Conference 3DelMar Pharmaceuticals Announces Expansion of VAL-083 Development Program to Include Ovarian Cancer 2DelMar Pharmaceuticals Announces Expansion of VAL-083 Development Program to Include Ovarian Cancer 3DelMar Pharmaceuticals Announces Expansion of VAL-083 Development Program to Include Ovarian Cancer 4
... 2011 BioNeutral Group, Inc. (OTC Bulletin Board: ... today announced the formation of BioNeutral Services, Inc., a ... appointment of Frank Battafarano as the Chairman and Chief ... Services will market and distribute a family of BioNeutral ...
... Inc. (Nasdaq: PCRX ), an emerging specialty pharmaceutical ... of 6,000,000 shares of its common stock at $7.00 per ... stock is being offered by Pacira. The shares are expected ... symbol "PCRX" on February 3, 2011. In addition, Pacira has ...
Cached Medicine Technology:BioNeutral Group Announces the Formation of Kentucky-Based BioNeutral Services, Inc. and the Appointment of Frank Battafarano as Chairman and CEO of BioNeutral Services, Inc. 2BioNeutral Group Announces the Formation of Kentucky-Based BioNeutral Services, Inc. and the Appointment of Frank Battafarano as Chairman and CEO of BioNeutral Services, Inc. 3Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering 2
(Date:9/2/2015)... ... ... Every year at this time, students prepare to go back to school. ... the academic workload confronting them. They just don’t have the skills needed to do ... students how to study. , “Bankers bank. Salesmen sell. Teachers teach. The job of ...
(Date:9/2/2015)... ... September 02, 2015 , ... Amada Senior Care, premier provider ... Kansas – its Johnson County location. Amada franchise partners Mike and Mell ... registered nurse background and spent over 20 years in medical device sales while Mell ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... Fort Lauderdale, CENTURION SERVICE GROUP is internationally known as an industry leader specializing ... house in the world, selling more than 100,000 pieces of medical equipment every ...
(Date:9/2/2015)... Utah (PRWEB) , ... September 02, 2015 , ... On ... Utah to attend doTERRA’s annual convention, the largest single-company convention to date for the ... Advocates and look forward to a tremendous event,” states David Stirling, doTERRA CEO. “One ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... pioneer in marine cosmetics introduces PIONNIÈRE XMF Perfection Youth Rich Cream , ... combines breakthrough biotechnological anti-aging power with a lipid-replenishing marine oil for intense nourishing ...
Breaking Medicine News(10 mins):Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 2Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 3Health News:Amada Senior Care Expands to Greater Kansas City 2Health News:Over 1800 Lots of Surplus Used Medical Equipment 2Health News:Over 1800 Lots of Surplus Used Medical Equipment 3Health News:doTERRA to Host the Largest Single-Company Convention in the State of Utah 2Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 2Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 3Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 4
... venom of the brown recluse spider, researchers at the University ... to open// molecular pores, called ion channels, in the membrane ... Lu, MD, PhD; Yajamana Ramu, PhD; and Yanping Xu, MD, ... venoms from over 100 poisonous invertebrate species to make this ...
... today launched a new vision correction technology, Zyoptix Aspheric, ... ,"There are 60 clinics all across India which use ... be upgraded to Zyoptix Aspherix which further reduces post ... and Lomb India Director-Surgical business Rajat Goel told reporters ...
... like corks to block oxygen flow to tumors, or to ... to a tumor is called embolization, and using gas bubbles ... promising is that the technique allows doctors to control exactly ... to surrounding tissue is minimal, said Joseph Bull, assistant professor ...
... by Dr. Adam Godzik at the Burnham Institute for ... understanding of information gathered// from the human genome project. ... a three year period, this consortium, under the name ... adequate support to scientists from Burnham and UCSD's Computer ...
... labs of Yale Goldman, MD, PhD, Director of the ... of Medicine,// and Erika Holzbaur, PhD, Professor of Physiology, ... show proteins that function as molecular motors are surprisingly ... cell. These observations could lead to better ways to ...
... Once a month osteoporisis drug and extra telephone support from ... among women for their drug treatment// than those who took ... issue of IJCP, the International Journal of Clinical Practice. ... part in the PERSIST study between January 2005 and January ...
Cached Medicine News:Health News:New Way to Open Cellular Ion Channels, Implications for Drug Design 2Health News:Researchers Use Bubbles in Cancer Treatment and Drug Delivery 2Health News:Joint Center for Molecular Modeling Instituted by Burnham Institute for Medical Research & UC San Diego 2Health News:Discovery of Agile Molecular Motors Could Aid in Treating Motor Neuron Diseases 2Health News:Women More Persistent with Monthly Osteoporosis Treatment 2
... The Stryker Cross-Screw System ... and secure method for ACL ... The Stryker Cross-Screw System provides ... fixation. The implant comes in ...
... Universal Wedge Screw is a ... cruciate reconstruction and is indicated ... grafts. The Universal Wedge Screw ... has blunt threads which protect ...
... The Stryker Threaded ... surgeon yet another choice ... tunnel. Dilators provide compaction ... The compaction of bone ...
... The Stryker Conquest Suture ... instruments that pierce through ... suture through the tissue ... The Conquest Retrievers are ...
Medicine Products: